FLT1 and breast carcinoma: For instance, sorafenib is a multikinase inhibitor involved in impairing the autophosphorylation of receptor tyrosine kinases such as VEGFR1, 2, and 3, PDGFRβ, and RET as these receptor tyrosine kinases typically involved in angiogenesis and tumor progression even in breast cancers [45, 46].